Rs 72 Lakh Cancer Drug Now Available At Rs 3 Lakh As Patent Ends: 24-Times Less Expensive Now


Rohit Kulkarni

Rohit Kulkarni

Mar 20, 2024


With the aim of improving affordability to the patients, a generic version of anti-cancer drug olaparib has been introduced by Zydus Lifesciences of India. The reduced cost of the medicine reduces the overall cost of the treatment. Used in treatment of cancers ranging from breast, ovarian, prostate, and pancreatic, this generic medicine targets specific genetic mutations which is associated with these cancers, enabling tailored treatment.

Rs 72 Lakh Cancer Drug Now Available At Rs 3 Lakh As Patent Ends: 24-Times Less Expensive Now

Zydus’ Affordable Olaparib & Sigh of Relief for Indian Cancer Patients

Majority of the 1.4 million new cancer cases in India can be treatable with this medicine. Zydus hopes to address and ease the financial burden on the patients with this economical alternative. Historically, there has been a demand to reduce the high cost of original dose, and the invent of olaparib substantially improves the patient access to vital medication.

The reason why the drug could be made affordable was the expiration of certain patents, hence paving the way for the invent of affordable versions. 

Patent & Their Impact on Healthcare Access

A generic olaparib launch was pioneered by Natco Pharma. This latest development in the pharma and medical world also brings forth the need for systematic evaluation of patent-related effects on healthcare access and underscores the patent impact on medicine accessibility.

Emphasizing the need to address patent-related barriers by some institutional barriers, Lawyer K. Gopakumar advocates for leveraging existing legal provisions to improve medicine access.

Speaking about the drug, then the usage of the same across stages of cancer highlights its versatility in treatment methods. This further lays importance on the fact that the drug’s affordability as well as accessibility was a major roadblock for it to truly help cancer patients across financial strata.


Rohit Kulkarni
Rohit Kulkarni
  • 1087 Posts

Subscribe Now!

Get latest news and views related to startups, tech and business

You Might Also Like

Business
Dec. 8, 2022

Beat The Burden Of Medical Inflation With A Health Insurance

As disease rates rise and medical technology develops, treatment costs climb. It’s essential to understand that medical costs are not exclusively associated with hospitals. The cost of prescription drugs, diagnostic procedures, ambulance and operating room fees, consultations with doctors, and other costs are also constantly increasing. All of them could put a big strain on […]

Business
Dec. 8, 2022

3 Biggest Changes Of iOS 16.2 Update That Every iPhone User Should Know!

In its latest update Apple said that it is preparing for the iOS 16.2 update for iPhones across the world. Notably, like the previous release, there are a couple of changes coming for the iPhones.  iOS 16.2 Update Release Date So far, Apple has not announced a release date for iOS 16.2 update. Reportedly, the […]

Business
Dec. 8, 2022

300 Microsoft Employees Create Employee Union, First Time Ever: This Is How Microsoft Reacted

Around 300 workers at Microsoft Corp.’s ZeniMax Studios have commenced the process of forming a union which is said to be the first at the software giant in the US.  Here, Microsoft Corp.’s ZeniMax Studios known for popular video games including Skyrim and Fallout. Forming Union In Microsoft Corp Moreover, the quality assurance employees at […]

Business
Dec. 7, 2022

India Beats China In Air Travel Safety: Ranking Jumps From 102 To 48 In Global Aviation Safety

India’s air safety protocols and executions have improved drastically over the years, as validated by the findings of a specialized agency of the United Nations, the International Civil Aviation Organization or ICAO. The UN watchdog has upgraded India’s ranking in terms of aviation safety to the 48th position, jumping past the rankings of countries like […]

Recent Posts

Related Videos

   

Subscribe Now!

Get latest news and views related to startups, tech and business

who's online